Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acella Pharmaceuticals has filed abbreviated new drug application (ANDA) with FDA for a product in the upper respiratory therapeutic area.
Subscribe to our email newsletter
The filing represents the fifth ANDA Acella has waiting approval from the FDA, the company said.
Acella develops a range of specialty pharmaceutical and other products in the areas of dermatology, women’s health, pediatrics and other applications.
Acella R&D head and vice president Allen Fields said the filing speaks to the quality of work performed by their team.
Acella CEO Mark Pugh said the filing is another example of their investment in new products and expansion of their diversified product portfolio.